Skip to Content
Merck
All Photos(2)

Documents

PZ0012

Sigma-Aldrich

Sunitinib malate

≥98% (HPLC), powder, receptor tyrosine kinase inhibitor

Synonym(s):

N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt, SU 011248, SU 11248, SU112248

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C22H27FN4O2 · C4H6O5
CAS Number:
341031-54-7
Molecular Weight:
532.56
MDL number:
MFCD08282795
UNSPSC Code:
12352200
PubChem Substance ID:
329823681
NACRES:
NA.77

product name

Sunitinib malate, ≥98% (HPLC)

Quality Level

100

Assay

≥98% (HPLC)

form

powder

solubility

DMSO: >10 mg/mL

storage temp.

room temp

SMILES string

O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C

InChI

1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1

InChI key

LBWFXVZLPYTWQI-IPOVEDGCSA-N

Gene Information

human ... CSF1R(1436) , FLT1(2321) , FLT3(2322) , FLT4(2324) , KDR(3791) , KIT(3815) , PDGFRA(5156) , PDGFRB(5159) , RET(5979)

Looking for similar products? Visit Product Comparison Guide

Application

Sunitinib malate has been used:
  • to study its mechanism in the inhibition of MCF-7 cell migration and angiogenesis
  • as a reference molecule to compare its docking energies with other ligands/vascular endothelial growth factor receptor (VEGF) receptor blocker
  • used in proliferation assay

Biochem/physiol Actions

Sunitinib has greater bioavailability and potency compared to other inhibitors. It prevents angiogenesis.
Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H360,H372

Hazard Classifications

Repr. 1B - STOT RE 1 Oral

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 10

1 of 10

Toceranib ≥98% (HPLC)

Sigma-Aldrich

PZ0338

Toceranib

Vatalanib dihydrochloride ≥98% (HPLC)

Sigma-Aldrich

SML2498

Vatalanib dihydrochloride

Dasatinib ≥98% (HPLC)

Sigma-Aldrich

SML2589

Dasatinib

Erlotinib hydrochloride

Sigma-Aldrich

CDS022564

Erlotinib hydrochloride

Imatinib mesylate ≥98% (HPLC)

Sigma-Aldrich

SML1027

Imatinib mesylate

SILu™Lite SigmaMAb Bevacizumab Monoclonal Antibody recombinant, expressed in CHO cells

Sigma-Aldrich

MSQC20

SILu™Lite SigmaMAb Bevacizumab Monoclonal Antibody

Lapatinib ≥98% (HPLC)

Sigma-Aldrich

SML2259

Lapatinib

Sorafenib tosylate ≥98% (HPLC)

Sigma-Aldrich

SML2633

Sorafenib tosylate

Imatinib

Sigma-Aldrich

CDS022173

Imatinib

APY29 ≥97% (HPLC)

Sigma-Aldrich

SML2381

APY29

Sunitinib: from rational design to clinical efficacy
Chow LQM and Eckhardt SG
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(7), 884-896 (2007)
Sunitinib treatment inhibited human breast cancer cell migration through regulation furin interaction with substrates
Jin SJ, et al.
International Journal of Clinical and Experimental Medicine, 9(2), 2535-2541 (2016)
Iris Uribesalgo et al.
EMBO molecular medicine, 11(8), e9266-e9266 (2019-07-04)
Angiogenesis is a hallmark of cancer, promoting growth and metastasis. Anti-angiogenic treatment has limited efficacy due to therapy-induced blood vessel alterations, often followed by local hypoxia, tumor adaptation, progression, and metastasis. It is therefore paramount to overcome therapy-induced resistance. We
Michael P Stany et al.
PloS one, 6(7), e21121-e21121 (2011-07-15)
Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer prognosis than serous and endometrioid histotypes. Despite this, patients with these tumors are treated in a similar fashion as all other
Suma Choorapoikayil et al.
Disease models & mechanisms, 6(5), 1159-1166 (2013-05-31)
Angiogenesis, the emergence of vessels from an existing vascular network, is pathologically associated with tumor progression and is of great interest for therapeutic intervention. PTEN is a frequently mutated tumor suppressor and has been linked to the progression of many
View All Related Papers

Related Content

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service